Depemokimab

Modify Date: 2024-04-07 09:40:37

Depemokimab structure	Common Name	Depemokimab
	CAS Number	2243274-14-6	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Depemokimab

Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody. Depemokimab can be used for research of asthma[1][2].

Name	Depemokimab

Description	Depemokimab (GSK-3511294) is a long-acting anti-IL-15 monoclonal antibody. Depemokimab can be used for research of asthma[1][2].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Interleukin Related Research Areas >> Inflammation/Immunology
Target	IL-15[1]
In Vivo	Depemokimab (食蟹猴药代动力实验) 与 Mepolizumab (HY-P9945) 相比，清除率降低约 2 倍，IL-5 结合亲和力比 Mepolizumab 高约 30 倍[2]。
References	[1]. Calzetta L, et al. Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma. Biomedicines. 2022 Sep 19;10(9):2330. [2]. Singh D, et al. A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma. Br J Clin Pharmacol. 2022 Feb;88(2):702-712.

No Any Chemical & Physical Properties